Day: April 29, 2024

Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye diseases TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA® HD (aflibercept) Injection 8 mg. The presentations are part of 14 accepted abstracts on EYLEA HD and EYLEA® (aflibercept) Injection 2 mg that will be shared at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting from May 5 to 9 in Seattle. “Our extensive data presentations at ARVO showcase the differentiated efficacy, safety and durability of EYLEA HD, and...

CNH_Intelsat Annoucement_1920x1080CNH collaborates with Intelsat to provide ruggedized connectivity to farmers in remote locationsCNH expands network connectivity with Intelsat collaboration Field-ready connectivity option for hard-to-reach locations brings the power of precision agriculture to more CNH customers  Basildon, April 29, 2024 CNH (NYSE: CNHI) and Intelsat, operator of one of the world’s largest integrated satellite and terrestrial communication networks, today announced a collaboration that will be the first to provide farmers ubiquitous access to the internet via a ruggedized satellite communications (SATCOM) service. Based on a new memorandum of understanding, Intelsat will provide multi-orbit internet access to connect CNH equipment working in remote locations and easy-to-use satellite terminals ready to handle...

Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on April 27, 2024, it received formal notice from The Nasdaq Stock Market, LLC’s Office of General Counsel (“Nasdaq”). This notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq’s Listing Rule 5550(a)(2) (the “Bid Price Rule”). Nasdaq noted that since April 9, 2024, Allarity’s stock has maintained a closing bid price above $1.00 per share for more than ten consecutive trading days, thereby meeting the requirements for regaining compliance. Thomas Jensen, CEO of Allarity Therapeutics, stated, “We are very pleased to announce NASDAQ’s confirmation of our...

SHANGHAI, China, April 29, 2024 (GLOBE NEWSWIRE) — ECARX Holdings, Inc. (Nasdaq: ECX) (“ECARX”), a global mobility tech provider, today announced that it will report its financial results for the first quarter of 2024 before the U.S. market opens on Monday, May 20, 2024. Company management will hold an earnings conference call via live audio webcast to discuss the financial results and will be available to answer questions from analysts and institutional investors. Earnings Conference Call & Webcast Details:Date: Monday, May 20, 2024Time: 8:00am ESTWebcast: https://edge.media-server.com/mmc/p/ji9r3h9b To join the live conference call, please register at https://register.vevent.com/register/BIeacb8a83827e45b4a0aa74556624b2c5 to receive the conference call details as well as international access numbers. Please join...

VANCOUVER, British Columbia, April 29, 2024 (GLOBE NEWSWIRE) — Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) (“Liberty Gold” or the “Company”) is pleased to announce a non-brokered, private placement financing raising proceeds of up to C$9.50 million (the “Offering”). The Offering will consist of the issuance of up to 27,142,858 units of the Company (the “Units”) at an issue price of C$0.35 per Unit. Each Unit will consist of one common share of Liberty Gold (each, a “Common Share”) and 1/2 of a common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to acquire one common share of Liberty Gold at a price of C$0.45 for a period of 24 months following completion of the Offering. The proceeds of the Offering will be used for exploration drilling on seven high-priority target areas identified at Black Pine, engineering,...

NEWMARKET, Ontario, April 29, 2024 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX: BOS) (OTCQX:ABSSF) (the “Company” or “AirBoss”) today announced that its wholly-owned subsidiary, AirBoss Defense Group (“ADG”), has been awarded a contract valued at up to US$45 million to provide its Bandolier lightweight, multipurpose energetic system to a NATO partner nation. Subject to satisfaction of customary conditions, including obtaining required export documentation, deliveries under this contract are expected to commence in the second half of 2024 and continue through to the end of 2025. The Bandolier is a lightweight and modular energetic system that can be employed across mobility, counter mobility, and survivability mission profiles. The Bandolier is designed to bridge the identified capability gap between large, complex, single...

XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3 clinical trial data X4 granted Rare Pediatric Disease Priority Review Voucher (PRV) concurrent with approval Conference call and webcast to be hosted today at 8:30 am ET BOSTON, April 29, 2024 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has approved XOLREMDI™ (mavorixafor) capsules for use in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. XOLREMDI, a selective CXC chemokine...